Fecha de publicación: 14 May 2018
Autores: Matthew D. Hellmann, Tavi Nathanson, Hira Rizvi, Benjamin C. Creelan, Francisco Sanchez-Vega, Arun Ahuja, Ai Ni, Jacki B. Novik, Levi M.B. Mangarin…
Background: Combination immune checkpoint blockade has demonstrated promising benefit in lung cancer, but predictors of response to combination therapy are unknown. Using whole-exome sequencing to examine non-small-cell lung cancer (NSCLC) treated with PD-1 plus CTLA-4 blockade, we found that high tumor mutation burden (TMB) predicted improved objective response, durable benefit, and progression-free survival.